Cargando…

Natural immunity helps overcome the age-related decline of SARS-CoV-2 vaccine immunogenicity

Detalles Bibliográficos
Autores principales:	Verschoor, Chris P, Haynes, Laura
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Author(s). Published by Elsevier Ltd. 2022
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9252531/ https://www.ncbi.nlm.nih.gov/pubmed/35813277 http://dx.doi.org/10.1016/S2666-7568(22)00146-5

Ejemplares similares

Estimating SARS-CoV-2 seroprevalence in long-term care: a window of opportunity
por: Verschoor, Chris P, et al.
Publicado: (2022)

SARS-CoV-2 and HIV-1 — a tale of two vaccines
por: Haynes, Barton F.
Publicado: (2021)

Effectiveness of SARS-CoV-2 vaccines in the post-natural infection world
por: Garg, Pramod Kumar, et al.
Publicado: (2022)

Waning immunity to SARS-CoV-2: implications for vaccine booster strategies
por: Altmann, Daniel M, et al.
Publicado: (2021)

Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination
por: Anderson, Roy M, et al.
Publicado: (2020)

Vaccination and protective immunity to SARS-CoV-2 omicron variants in people with immunodeficiencies
por: Nadesalingam, Angalee, et al.
Publicado: (2023)

Hybrid immunity versus vaccine-induced immunity against SARS-CoV-2 in patients with autoimmune rheumatic diseases
por: Shenoy, Padmanabha, et al.
Publicado: (2022)

Bell's palsy and SARS-CoV-2 vaccines
por: Ozonoff, Al, et al.
Publicado: (2021)

SARS-CoV-2 vaccination in people with HIV
por: Spinelli, Matthew A
Publicado: (2021)

Optimising SARS-CoV-2 vaccination schedules
por: Belda-Iniesta, Cristobal
Publicado: (2021)

SARS-CoV-2: from herd immunity to hybrid immunity
por: Goldblatt, David
Publicado: (2022)

Risk of SARS-CoV-2 reinfection after natural infection
por: Boyton, Rosemary J, et al.
Publicado: (2021)

Cellular and humoral immunity after the third dose of SARS-CoV-2 vaccine in patients treated with rituximab
por: Felten, Renaud, et al.
Publicado: (2022)

Working towards a comprehensive appraisal of vaccine-induced immunity against SARS-CoV-2 in IBD
por: Otten, Antonius T, et al.
Publicado: (2023)

Recombinant protein vaccines against SARS-CoV-2
por: Gilbert, Sarah C, et al.
Publicado: (2021)

SARS-CoV-2 evolution and vaccines: cause for concern?
por: Williams, Thomas C, et al.
Publicado: (2021)

Stroke after SARS-CoV-2 vaccination: Comment
por: Kleebayoon, Amnuay, et al.
Publicado: (2023)

Immunogenic cell death and immunogenic surrender: related but distinct mechanisms of immune surveillance
por: Mezzapelle, Rosanna, et al.
Publicado: (2021)

The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines
por: Shang, Weilong, et al.
Publicado: (2020)

SARS-CoV-2 vaccines: fast track versus efficacy
por: Alkandari, Dana, et al.
Publicado: (2021)

Will SARS-CoV-2 variants of concern affect the promise of vaccines?
por: Gupta, Ravindra K.
Publicado: (2021)

Single-dose SARS-CoV-2 vaccination efficacy in the elderly
por: Prendecki, Maria, et al.
Publicado: (2021)

Balancing risk and benefit of SARS-CoV-2 vaccines in children
por: Levin, Michael, et al.
Publicado: (2022)

Affordable SARS-CoV-2 protein vaccines for the pandemic endgame
por: Triccas, James A., et al.
Publicado: (2022)

Guillain-Barre syndrome related to SARS-CoV-2 vaccinations
por: Finsterer, Josef, et al.
Publicado: (2022)

SARS-CoV-2 vaccine strategies in kidney transplant recipients
por: Prendecki, Maria, et al.
Publicado: (2023)

Stroke seven hours after SARS-CoV-2 vaccination
por: Fiorini, Ana Claudia, et al.
Publicado: (2023)

Pre-existing immunity to SARS-CoV-2: the knowns and unknowns
por: Sette, Alessandro, et al.
Publicado: (2020)

Endemic SARS-CoV-2 will maintain post-pandemic immunity
por: Veldhoen, Marc, et al.
Publicado: (2021)

SARS-CoV-2 immunity and HIV infection: total recall?
por: Dauby, Nicolas, et al.
Publicado: (2021)

A promising inactivated whole-virion SARS-CoV-2 vaccine
por: Isakova-Sivak, Irina, et al.
Publicado: (2021)

SARS-CoV-2 vaccination and phase 1 cancer clinical trials
por: Yap, Timothy A, et al.
Publicado: (2021)

SARS-CoV-2 vaccination in IBD: more pros than cons
por: D’Amico, Ferdinando, et al.
Publicado: (2021)

Efficacy of an adenovirus type 5 vectored SARS-CoV-2 vaccine
por: Kennedy, Richard B
Publicado: (2022)

Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma
por: Lim, Sean H, et al.
Publicado: (2021)

Managing waning vaccine protection against SARS-CoV-2 variants
por: Leung, Kathy, et al.
Publicado: (2022)

The immune system of children: the key to understanding SARS-CoV-2 susceptibility?
por: Carsetti, Rita, et al.
Publicado: (2020)

Protective immunity after recovery from SARS-CoV-2 infection
por: Kojima, Noah, et al.
Publicado: (2022)

SARS-CoV-2 hybrid immunity: silver bullet or silver lining?
por: Suryawanshi, Rahul, et al.
Publicado: (2022)

Jigsaw puzzle of SARS-CoV-2 RBD evolution and immune escape
por: Yi, Chunyan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_omekhu600lo1bmalvc0e3lta08